公开(公告)号：WO2008007930A9

公开(公告)日：2008-01-17

申请号：PCT/KR2007/003429

申请日：2007-07-13

Applicant: LG LIFE SCIENCES LTD. ,  CHOI, Sung Pil ,  AHN, In Ae ,  LEE, Sang Hyup ,  LEE, Sang Dae ,  SHIN, Mi Sook ,  LEE, Koo ,  CHOI, Deog Young ,  SHIM, Dong Sup ,  YIM, Hyeon Joo ,  YOON, Min Kyung ,  CHUNG, Soo Yong ,  LEE, Jung Ae ,  HA, Yong Hwa ,  KIM, Young Kwan ,  PARK, Oeuk ,  LEE, Hyun Min ,  KIM, Youn Hoa

Inventor： CHOI, Sung Pil ,  AHN, In Ae ,  LEE, Sang Hyup ,  LEE, Sang Dae ,  SHIN, Mi Sook ,  LEE, Koo ,  CHOI, Deog Young ,  SHIM, Dong Sup ,  YIM, Hyeon Joo ,  YOON, Min Kyung ,  CHUNG, Soo Yong ,  LEE, Jung Ae ,  HA, Yong Hwa ,  KIM, Young Kwan ,  PARK, Oeuk ,  LEE, Hyun Min ,  KIM, Youn Hoa

IPC: C07D403/06

Abstract: The present invention relates to a compound of the following formula 1, pharmaceutically acceptable salt and isomer thereof effective as agonist of melanocortin receptor, and an agonistic composition of melanocortin receptor comprising the same as active ingredient.

公开(公告)号：WO2008007930A1

公开(公告)日：2008-01-17

申请号：PCT/KR2007003429

申请日：2007-07-13

Applicant: LG LIFE SCIENCES LTD ,  CHOI SUNG PIL ,  AHN IN AE ,  LEE SANG HYUP ,  LEE SANG DAE ,  SHIN MI SOOK ,  LEE KOO ,  CHOI DEOG YOUNG ,  SHIM DONG SUP ,  YIM HYEON JOO ,  YOON MIN KYUNG ,  CHUNG SOO YONG ,  LEE JUNG AE ,  HA YONG HWA ,  KIM YOUNG KWAN ,  PARK OEUK ,  LEE HYUN MIN ,  KIM YOUN HOA

Inventor： CHOI SUNG PIL ,  AHN IN AE ,  LEE SANG HYUP ,  LEE SANG DAE ,  SHIN MI SOOK ,  LEE KOO ,  CHOI DEOG YOUNG ,  SHIM DONG SUP ,  YIM HYEON JOO ,  YOON MIN KYUNG ,  CHUNG SOO YONG ,  LEE JUNG AE ,  HA YONG HWA ,  KIM YOUNG KWAN ,  PARK OEUK ,  LEE HYUN MIN ,  KIM YOUN HOA

IPC: C07D403/06

CPC classification number: C07D207/16 ,  C07D207/48 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention relates to a compound of the following formula 1, pharmaceutically acceptable salt and isomer thereof effective as agonist of melanocortin receptor, and an agonistic composition of melanocortin receptor comprising the same as active ingredient.

Abstract translation: 本发明涉及有效作为黑皮质素受体激动剂的下式1化合物，其药学上可接受的盐和异构体，以及包含与活性成分相同的黑皮质素受体激动剂组合物。

公开(公告)号：WO2005047251A1

公开(公告)日：2005-05-26

申请号：PCT/KR2004/002929

申请日：2004-11-12

Applicant: LG LIFE SCIENCES LTD. ,  YAMANOUCHI PHARMACEUTICAL CO., LTD. ,  LEE, Koo ,  PARK, Heui-Sul ,  AHN, In-Ae ,  YOO, Hyun-Ju ,  KIM, Jong-Yup ,  CHOI, Deog-Young ,  YIM, Hyeon-Joo ,  CHUNG, Kyung-Ha ,  SHIM, Dong-Sup ,  LEE, Sang-Kyun ,  KONDOH, Yutaka ,  HIRABAYASHI, Ryoji ,  HONDA, Shugo ,  KAKU, Hidetaka ,  SHISHIKURA, Jun-Ichi ,  ITO, Hiroyuki ,  KURAMA, Takeshi

Inventor： LEE, Koo ,  PARK, Heui-Sul ,  AHN, In-Ae ,  YOO, Hyun-Ju ,  KIM, Jong-Yup ,  CHOI, Deog-Young ,  YIM, Hyeon-Joo ,  CHUNG, Kyung-Ha ,  SHIM, Dong-Sup ,  LEE, Sang-Kyun ,  KONDOH, Yutaka ,  HIRABAYASHI, Ryoji ,  HONDA, Shugo ,  KAKU, Hidetaka ,  SHISHIKURA, Jun-Ichi ,  ITO, Hiroyuki ,  KURAMA, Takeshi

IPC: C07D207/16

CPC classification number: C04B35/632 ,  C07D205/04 ,  C07D207/14 ,  C07D211/58 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12

Abstract: The present invention relates a compound of formula 1, and pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof effective as agonist of melanocortin receptor, and an agonistic composition of melanocortin receptor comprising the same as active ingredient.

Abstract translation: 本发明涉及作为黑皮质素受体激动剂有效的式1化合物及其药学上可接受的盐，水合物，溶剂化物或异构体，以及包含其作为活性成分的黑皮质素受体激动剂组合物

公开(公告)号：WO2012111995A1

公开(公告)日：2012-08-23

申请号：PCT/KR2012/001185

申请日：2012-02-16

Applicant: LG LIFE SCIENCES LTD. ,  KIM, Young Kwan ,  JOO, Hyun Woo ,  KIM, Myoung Yeol ,  PARK, Heui Sul ,  LEE, Tae Hee ,  KWAK, Hyo Shin ,  SHIM, Dong Sup ,  CHOI, Eun Sil

Inventor： KIM, Young Kwan ,  JOO, Hyun Woo ,  KIM, Myoung Yeol ,  PARK, Heui Sul ,  LEE, Tae Hee ,  KWAK, Hyo Shin ,  SHIM, Dong Sup ,  CHOI, Eun Sil

IPC: C07D401/14 ,  C07D401/12 ,  A61K31/4523 ,  A61P3/00

CPC classification number: C07D451/06 ,  C07D211/46 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D413/04 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14

Abstract: The present invention relates to oxime derivatives, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The oxime derivatives according to the present invention act as GPR119 agonists to stimulate the secretion of insulin and promote GLP-1 formation for preventing or treating type 2 diabetes, complications of diabetes, obesity, dyslipidemia or osteoporosis.

Abstract translation: 本发明涉及肟衍生物，其制备方法，包含其的药物组合物及其应用。 根据本发明的肟衍生物用作GPR119激动剂以刺激胰岛素的分泌并促进用于预防或治疗2型糖尿病，糖尿病并发症，肥胖症，血脂异常或骨质疏松症的GLP-1形成。